Skip to Content Skip to Navigation
27th April 2023 Lung Cancer

Blood test to monitor treatment for deadliest cancer

COVID 19, lung disease

Did you know lung cancer is the most common cause of cancer-related death in Australia?

On average, people diagnosed with lung cancer have less than a one-in-five chance of surviving five years after being diagnosed. With such a significant burden, the need to better understand this disease and find more effective therapies is critical.

That is why The Hospital Research Foundation Group is proud to be partnering with Flinders Foundation to fund research into improving treatments and care for lung cancer.

Flinders Medical Centre Senior Consultant Respiratory and Sleep Medicine, Dr Anand Rose (pictured), has received a Southern Adelaide Local Health Network (SALHN) Enquiry Grant for research into a novel blood test could be used to monitor the treatment of lung cancer.

“Of the cancers in the body, advanced lung cancer is one of the most difficult to treat,” Dr Rose says.

“This blood test could be a useful addition in the doctor’s toolkit to determine if the cancer treatment has been effective, and for informing the patient and doctor if the cancer has returned, without the need for performing invasive biopsies.

“This is exciting work in the lung cancer space, and it’s hoped it will ease our patient’s journeys in a small way as they battle this deadly disease,” Dr Rose says.

We look forward to keeping you updated.